spacer
home > ebr > winter 2019 > channelling the future of liposome generation
PUBLICATIONS
European Biopharmaceutical Review

Channelling the Future of Liposome Generation

The pharmaceutical industry has increasingly adopted liposomes as a means of drug delivery thanks to their biocompatibility and suitability for both hydrophilic and hydrophobic substrates. A number of factors, such as average diameter, size distribution, and lamellarity (number of bilayers), play a crucial role in determining the drug release profile, and existing batch production methods do not offer the level of control needed for fine-tuning of parameters. More recently, microfluidics has established itself as a desirable alternative, offering consistent particle diameters, narrow size distribution, and good batch-to-batch reproducibility.

Encapsulating a drug in a nano- or microparticle is an increasingly popular method for drug delivery. For starters, encapsulation protects an enclosed molecule from enzymatic or acidic degradation in the stomach, improves diffusion of the drug across the digestive tract, and provides a means by which hydrophobic molecules can be introduced into the body. Additionally, it enables the administration of a number of potential drugs, which often cannot be routinely used due to their toxicity and associated side effects. Despite their excellent antimicrobial properties, these drugs frequently display poor pharmacokinetics and pharmacodynamics – drawbacks that can be offset through encapsulation. Formulating these nanoor microparticles to extend their circulating half-life can help maintain higher therapeutic levels of the drug, reducing the number of doses a patient receives. A final consideration is the ability to modify the particle to encourage adsorption by specific cells. Binding proteins or antibodies to the external surface or adjusting the drug release profile to respond to a particular temperature or pH are all ways of introducing selective targeting, a powerful feature of drug delivery via encapsulation.

An Ideal Candidate

The liposome is one particular microparticle formulation that has attracted a lot of attention. Liposomes are vesicular nano- or microparticles consisting of one or more lipid bilayers encapsulating an internal aqueous core. The bilayers are made of amphiphilic phospholipids – two hydrophobic fatty acid ‘tails’ and a hydrophilic phosphate ‘head’ – which aggregate and self-assemble, exposing the phosphate groups to the aqueous environment and turning the fatty acid tails inwards. Cholesterol is often an additional component in the liposome membrane, thanks to the benefits it brings. It increases the thermal stability of the liposome, as well as reducing the membrane permeability, therefore aiding encapsulation and retention of the drug until it is ready to be released.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
After completing his Master’s degree in chemical engineering, Damiano Rossi joined the University of Pisa, Italy, as a material scientist working on the formulation of new energetic copolymer binders and adhesive membranes. He obtained a PhD in chemical engineering from University College London, UK, where he worked on the development of microfluidic devices for continuous sonocrystallisation of APIs. Today, Damiano is a technical applications specialist at Blacktrace, where he is responsible for overseeing applications relating to particle engineering and Dolomite Microfluidics’ products.

After completing a Bachelor’s degree in chemical and biological engineering, Anna Blakney pursued a PhD in bioengineering at the University of Washington, US, with a focus on the development of electrospun fibers for multipurpose prevention of pregnancy and HIV. She is now a postdoctoral research fellow at Imperial College London, UK. Anna’s current research is on the formulation of self-amplifying RNA vaccines, including nanoparticle systems, such as liposomes and polyplexes, for optimal cellular uptake, expression, and immunogenicity.
spacer
Damiano Rossi
spacer
spacer
spacer
Anna Blakney
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cambridge Sensotec (manufacturers of Dynascan) obtains new ISO accreditation

On the 30th May 2019, Cambridge Sensotec proudly achieved ISO 9001:2015 accreditation under the BSI (British Standards Institution). Cambridge Sensotec Ltd now joins 1.3 million companies across 112 countries worldwide that hold this prestigious certificate.
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement